As of 2025-10-16, the Intrinsic Value of Cardiol Therapeutics Inc (CRDL.TO) is -2.18 CAD. This CRDL.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.46 CAD, the upside of Cardiol Therapeutics Inc is -249.63%.
Based on its market price of 1.46 CAD and our intrinsic valuation, Cardiol Therapeutics Inc (CRDL.TO) is overvalued by 249.63%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -2.18 - -2.18 | -2.18 | -249.63% |
| P/E | (3.22) - (4.56) | (3.91) | -367.8% |
| DDM - Stable | (3.71) - (13.06) | (8.38) | -674.1% |
| DDM - Multi | (0.60) - (1.66) | (0.88) | -160.6% |
| Market Cap (mil) | 125.47 |
| Beta | 1.46 |
| Outstanding shares (mil) | 85.94 |
| Enterprise Value (mil) | 107.42 |
| Market risk premium | 5.10% |
| Cost of Equity | 9.63% |
| Cost of Debt | 5.00% |
| WACC | 9.62% |